Even though the scientific relevance with the aforementioned cardiovascular chance factor alterations by tirzepatide is going to be assessed from the planned cardiovascular consequence examine SURPASS-CVOT ( "form":"clinical-trial","attrs": "text":"NCT04255433","term_id":"NCT04255433" NCT04255433), a pre-specified cardiovascular meta-Assessment ind